GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InMed Pharmaceuticals Inc (NAS:INM) » Definitions » E10

INM (InMed Pharmaceuticals) E10 : $-728.32 (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is InMed Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

InMed Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was $-3.640. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-728.32 for the trailing ten years ended in Dec. 2024.

During the past 3 years, the average E10 Growth Rate was -3.70% per year. During the past 5 years, the average E10 Growth Rate was -4.90% per year. During the past 10 years, the average E10 Growth Rate was 9.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of InMed Pharmaceuticals was 29.40% per year. The lowest was -8.40% per year. And the median was 12.30% per year.

As of today (2025-03-14), InMed Pharmaceuticals's current stock price is $2.7266. InMed Pharmaceuticals's E10 for the quarter that ended in Dec. 2024 was $-728.32. InMed Pharmaceuticals's Shiller PE Ratio of today is .


InMed Pharmaceuticals E10 Historical Data

The historical data trend for InMed Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals E10 Chart

InMed Pharmaceuticals Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -645.32 -702.90 -791.58 -821.75 -784.95

InMed Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -826.48 -828.88 -784.95 -745.90 -728.32

Competitive Comparison of InMed Pharmaceuticals's E10

For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Shiller PE Ratio falls into.



InMed Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, InMed Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-3.64/127.3637*127.3637
=-3.640

Current CPI (Dec. 2024) = 127.3637.

InMed Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201503 -520.587 99.789 -664.439
201506 -285.290 100.500 -361.547
201509 -122.905 100.421 -155.879
201512 -118.903 99.947 -151.519
201603 -127.115 101.054 -160.211
201606 -128.789 102.002 -160.812
201609 -125.499 101.765 -157.069
201612 -122.759 101.449 -154.118
201703 -123.727 102.634 -153.540
201706 -263.161 103.029 -325.319
201709 -133.008 103.345 -163.921
201712 -131.213 103.345 -161.709
201803 -127.767 105.004 -154.974
201806 -241.668 105.557 -291.593
201809 -255.416 105.636 -307.951
201812 -242.286 105.399 -292.777
201903 -247.154 106.979 -294.248
201906 -357.033 107.690 -422.258
201909 -270.000 107.611 -319.559
201912 -240.000 107.769 -283.636
202003 -195.000 107.927 -230.117
202006 -155.000 108.401 -182.114
202009 -155.000 108.164 -182.513
202012 -185.000 108.559 -217.045
202103 -205.000 110.298 -236.719
202106 -204.200 111.720 -232.794
202109 -123.400 112.905 -139.203
202112 -154.600 113.774 -173.066
202203 -122.800 117.646 -132.944
202206 -260.800 120.806 -274.957
202209 -81.200 120.648 -85.720
202212 -18.200 120.964 -19.163
202303 -12.000 122.702 -12.456
202306 5.600 124.203 5.742
202309 -15.240 125.230 -15.500
202312 -3.710 125.072 -3.778
202403 -3.600 126.258 -3.632
202406 -3.800 127.522 -3.795
202409 -2.710 127.285 -2.712
202412 -3.640 127.364 -3.640

Add all the adjusted EPS together and divide 10 will get our e10.


InMed Pharmaceuticals  (NAS:INM) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


InMed Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


InMed Pharmaceuticals Business Description

Traded in Other Exchanges
Address
885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Executives
Mancini Alexandra Diane Janet officer: Sr VP, Clinical Reg Affairs C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Andrew Hull director C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Eric A Adams director, officer: President & CEO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Jonathan Tegge officer: Interim CFO 217 W. MAIN STREET, SOMERVILLE NJ 08876
Sarah Li officer: VP, Accounting and Controller 310-815 WEST HASTINGS ST., VANCOUVER Z4 V6C1B4
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
Bryan T Baldasare director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Brenda Edwards officer: Interim CFO 111-1232 JOHNSON ST., COQUITLAM A1 V3B 4T2
Janet P Grove director 510 WEST GEORGIA STREET, SUITE 1800, VANCOUVER A1 V5T 4T5
Bruce Colwill officer: CFO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Shane Aaron Johnson officer: SVP & GM of BayMedica LLC 930 TAHOE BLVD., SUITE 802-433, INCLINE VILLAGE NV 89451
Adam D. Cutler director 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
William J Garner director 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010
Catherine Sazdanoff director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric C Hsu officer: Sr. VP, Pre-Clinical Res/Dev C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4